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CLINICAL, PUBLIC HEALTH,AND ECONOMIC
ISSUES ASSOCIATED WITH SWITCHING
SECOND-GENERATION ANTIHISTAMINES FROM
PRESCRIPTION TO OVER-THE-COUNTER
Prasad M, Shih YCT, Luce BR
MEDTAP International Inc, Bethesda, MD, USA
OBJECTIVE: To compare this switch with prior Rx-
to-OTC switches and discuss its economic, clinical, and
public health implications.
METHODS: The FDA held meetings in May 2001 to
determine if prescription (Rx) second-generation antihis-
tamines (SGAs) should be sold over-the-counter (OTC).
This meeting warranted much attention because a party
other than drug manufacturers requested the switch, and
SGAs’ patents have not expired. Literature reviews of
prior switches and allergic rhinitis (epidemiology and
clinical management) were conducted. Microeconomic
theories were used to examine economic implications of
switching SGAs.
RESULTS: Past experiences of switching drugs to OTC
status (i.e., topical hydrocortisone, H2-blockers) have
resulted in lower prices and greater consumer surplus and
availability. It is unclear if similar conclusions can be
drawn about SGAs, whose patent protection differen-
tiates them from prior switches of patent-expired drugs.
Predictions of the switch’s economic consequences (i.e.,
pricing and social welfare) cannot be made without full
knowledge of demand elasticity in the antihistamine (ﬁrst-
and second-generation) market. Additionally, a mandated
switch prior to patent expiration may discourage research
and development. From a clinical perspective, selling
SGAs OTC may reduce physician intervention, leading 
to drug misuse and missed diagnoses of severe co-
morbidities (e.g., asthma). From a public health perspec-
tive, if SGAs are removed from Rx formularies post-
switch, patients could be responsible for total drug
acquisition costs. This may diminish availability for ﬁnan-
cially vulnerable populations (i.e., Medicaid recipients).
CONCLUSIONS: Selling SGAs OTC may increase avail-
ability and decrease the use of sedating antihistamines.
However, the net impact of their switch remains
unknown. The lack of generic competition implies prices
for SGAs may not fall nor may social welfare improve.
Cost-beneﬁt analyses are needed to determine if beneﬁts
of the switch will outweigh costs of misdiagnoses and
misuse. Lastly, the impact of the switch on vulnerable
populations must also be explored.
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PREGNANCY OUTCOMES IN WOMEN TAKING
ANTI-ASTHMATIC MEDICATIONS IN THE
GEORGIA MEDICAID POPULATION
Joseph GJ1, Kotzan JA2,Wade WE3
1Hines VA Hospital, Hines, IL, USA; 2University of Georgia,
Athens, GA, USA; 3University of Georgia College of
Pharmacy, Athens, GA, USA
OBJECTIVE: To determine the impact of anti-asthmatic
medications on pregnancy outcomes in the Georgia 
Medicaid population.
METHOD: Using Medicaid claims data from Georgia,
we examined pregnancy outcomes over six months from
January to June 1997. Medication and medical history
twelve months prior to each eligible outcome were 
examined. Abnormal pregnancy outcomes included:
spontaneous abortion, hemorrhage, pre-term infant 
and stillborn infants. Logistic regression model included 
pregnancy outcome as the dependent variable. The 
independent variables included age, race, Medicaid 
eligibility, diagnosis for asthma, anti-asthmatic medica-
tion, epilepsy, diabetes, AIDS, anemia, alcohol abuse,
drug abuse, psychosis, depression, tobacco abuse, bipolar
disorders and obesity.
RESULTS: There were 6,396 eligible women who had 
a pregnancy outcome in the six-month study period.
Logistic regression analysis indicated that consumption of
prescription drugs for asthma and other pulmonary con-
ditions increased the risk of an abnormal outcome by
36%. Comorbidities like depression and obesity increased
the risk of an abnormal outcome by 50% and 90%
respectively. Age of 35 or older, had an 89% increase in
abnormal outcomes.
CONCLUSIONS: We showed that women in the Georgia
Medicaid program had an increased risk of an abnormal
pregnancy outcome when using anti-asthmatic medica-
tions during pregnancy. This research has further 
substantiated the possible teratogenic effect hypothesis of
anti-asthmatic medications in pregnancy. Larger cohorts
of women need to be studied over a longer period of time
to fully explore this teratogenic relationship. Results may
have implications for more judicious use of such medica-




LONG-TERM BENEFITS OF CHEMOPREVENTIVE
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Borker R, Madhavan S, Simon K, Higa G,Amonkar M,
Scott V
West Virginia University, Morgantown, WV, USA
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OBJECTIVE: To estimate the long-term beneﬁts of
chemopreventive tamoxifen and mammography screen-
ing in women who are healthy but at high risk of devel-
oping breast cancer. Long-term beneﬁts were deﬁned in
terms of life expectancy (LE) gains achieved through 
addition of chemopreventive tamoxifen (5-year therapy)
to routine mammography screening.
METHOD: A Markov process with time-and-
state-dependent transition probabilities was developed.
Two hypothetical cohorts of high-risk women were 
initiated at age forty and were followed over their lifetime.
The ﬁrst cohort consumed tamoxifen and underwent
routine mammography screening as per recommendations
of the American Cancer Society (ACS). The second cohort
(control cohort) did not consume tamoxifen and under-
went mammography screening at rates observed in general
population settings (these rates are much lower than the
ones recommended by the ACS). Tamoxifen intervention
was modeled based on the 5-year Breast Cancer Preven-
tion Trial results. Data from published analyses, which
investigated effects of mammography screening on breast
cancer mortality, was used to model mammography
screening intervention. Mortality data were obtained from
life tables and other published sources.
RESULTS: Tamoxifen coupled with routine mammogra-
phy screening prolonged the average survival of cohort
members who started consuming the drug at age of forty
by 86.14 days as compared to the control group. One-way
sensitivity analysis was performed to evaluate the poten-
tial impact of each assumption on average cohort survival.
Sensitivity analysis involved varying intervention-related
effectiveness parameters, rates of intervention-related
adverse events, compliance with intervention, and mor-
tality rates associated with different health states in the
model. For all variations, tamoxifen plus routine mam-
mography screening group had higher average survival
than the control group.
CONCLUSION: The model was found to be robust to
sensitivity analysis and hence tamoxifen plus routine
mammography screening can be expected to increase 
survival among women who are at higher risk of 
breast cancer.
PCN2
AN INTERIM COST AND OUTCOME
COMPARISON ALONGSIDE A PROSPECTIVE
RANDOMIZED CLINICAL TRIAL COMPARING
EARLY INTENSIFICATION WITH BONE
MARROW TRANSPLANTATION (BMT) TO
CONVENTIONAL DOSE CHEMOTHERAPY FOR
PREVIOUSLY UNTREATED PATIENTS WITH
AGGRESSIVE NON-HODGKIN’S LYMPHOMA
Adamus AT,Arbuckle RB, King KM, Rodriguez MA
University of Texas M.D. Anderson Cancer Center, Houston,
TX, USA
OBJECTIVES: To identify and compare the costs 
and outcomes associated with early intensiﬁcation with
bone marrow transplantation versus conventional dose
chemotherapy for previously untreated patients with
aggressive non-Hodgkin’s lymphoma at high risk for
relapse.
METHODS: Costs and patient responses (outcomes)
were evaluated for the ﬁrst 84 patients in this ongoing
prospective randomized clinical trial. Data were compiled
from November 1995 until May 2001. Patient outcomes
were retrieved from the institutional Protocol Data 
Management System and costs were retrieved from 
institutional ﬁnancial and administrative databases.
Direct costs included hospital, clinic, pharmacy, and
physician costs. Pearson chi square was used to analyze
the association between costs and treatment group.
RESULTS: Forty-four patients received conventional 
dose chemotherapy and 40 patients received BMT. The 
average cost of therapy per patient for conventional dose
chemotherapy was $61,515 (range $5,360 to $186,684)
and the average cost per patient for BMT was $133,365
(range $11,868 to $431,248). Outcomes were categorized
as complete response (n = 36), partial response (n = 35),
and other (incomplete to date n = 13). Costs were 
categorized as low (<$45,000), medium ($45,000–
$80,999), medium high ($81,000–$125,999), and high
(>$126,000). In the conventional dose chemotherapy
group 61.1% of patients had a complete response and
38.9% of patients in the BMT group had a complete
response. Costs for conventional dose chemotherapy
patients were in the low to medium cost groups, and costs
for BMT patients were in the medium-high to high cost
groups (chi square = 29.422, d.f. = 3, p < 0.001).
CONCLUSIONS: Overall, higher costs were observed in
the BMT group, and more complete responses were
observed in the conventional dose chemotherapy group.
PCN3
COLLECTION OF INFECTIOUS DISEASE AND
ECONOMIC OUTCOMES FOR NON-HODGKIN’S
LYMPHOMA AND MULTIPLE MYELOMA
PATIENTS ADMITTED FOR INFECTIOUS
COMPLICATIONS UTILIZING A PALMTM
HANDHELD
King KM,Wood AM,Arbuckle RB, Adamus AT,
Hagemeister FB
University of Texas M.D. Anderson Cancer Center, Houston,
TX, USA
OBJECTIVES: To evaluate infectious disease outcomes
and cost of care for lymphoma and myeloma patients
admitted for infectious complications. To evaluate a 
Palm handheld as a tool for prospective data collection
utilizing Pendragon Forms software.
METHODS: Patients admitted to the Lymphoma/
Myeloma service receiving anti-infective therapy for
infectious diseases were followed. Targeted outcomes
were collected prospectively during hospitalization and
included length of hospitalization (days), adverse events
attributed to the anti-infective, febrile days (≥38.3°C),
